Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
May 27, 2016 7:00am EDT

Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update

May 02, 2016 7:00am EDT

Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association's Annual Meeting

Apr 29, 2016 7:00am EDT

Can-Fite to Present at Joseph Gunnar & Co.'s Pioneers 2016 Conference in New York City on May 5, 2016

Apr 11, 2016 7:00am EDT

Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose

Apr 04, 2016 7:00am EDT

Can-Fite to Participate in BIO-Europe Partnering Conference on April 4-6, 2016 in Stockholm, Sweden

Apr 01, 2016 7:00am EDT

Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update

Mar 17, 2016 7:00am EDT

Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis

Mar 03, 2016 7:00am EST

Can-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on March 7, 2016

Feb 05, 2016 7:00am EST

Can-Fite to Present at BIO CEO & Investor Conference in New York City on February 8, 2016

Jan 25, 2016 7:00am EST

Can-Fite CEO Dr. Pnina Fishman to Chair Scientific Session at the 2016 Purinergic Signaling and Cancer Immunotherapy Conference in Vancouver on January 26, 2016

  • arrow_back
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding